STOCK TITAN
  1. Home
  2. Sec-filings
  3. STOK
  4. [Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Stoke Therapeutics (STOK) director reports equity award vesting and share sales

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. reported insider equity transactions by a company director. On December 3, 2025, the director exercised 26,250 performance stock units at an exercise price of $0, receiving an equal number of common shares. On December 4 and 5, 2025, portions of these and other shares were sold in several market transactions at weighted average prices ranging from $30.23 to $31.96 per share.

One sale on December 4, 2025 is described as an issuer-mandated sale to cover tax withholding tied to the vesting and settlement of restricted stock units. Additional sales on December 5, 2025 were executed under a Rule 10b5-1 trading plan adopted on December 30, 2024. After all reported transactions, the director directly holds 62,554 shares of Stoke Therapeutics common stock, and no performance stock units remain from the reported award. The underlying award vested in two equal parts on December 3, 2024 and December 3, 2025.

Positive

  • None.

Negative

  • None.
Insider Kaye Edward M. MD
Role Director
Sold 15,001 shs ($467K)
Type Security Shares Price Value
Sale Common Stock 6,367 $31.3304 $199K
Sale Common Stock 1,681 $31.1468 $52K
Sale Common Stock 500 $31.846 $16K
Sale Common Stock 5,222 $30.7635 $161K
Sale Common Stock 1,231 $31.3164 $39K
Exercise Performance Stock Units 26,250 $0.00 --
Exercise Common Stock 26,250 $0.00 --
Holdings After Transaction: Common Stock — 64,735 shares (Direct); Performance Stock Units — 0 shares (Direct)
Footnotes (1)
  1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.69 to $31.61 per share, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $31.96 per share, inclusive. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kaye Edward M. MD
(Last) (First) (Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
(Street)
BEDFORD MA 01730
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/03/2025 M 26,250 A $0 77,555 D
Common Stock 12/04/2025 S(1) 5,222 D $30.7635(2) 72,333 D
Common Stock 12/04/2025 S(1) 1,231 D $31.3164(3) 71,102 D
Common Stock 12/05/2025 S(1) 6,367 D $31.3304(4) 64,735 D
Common Stock 12/05/2025 S(5) 1,681 D $31.1468(6) 63,054 D
Common Stock 12/05/2025 S(5) 500 D $31.846(7) 62,554 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Stock Units (8) 12/03/2025 M 26,250 (9) 12/03/2025 Common Stock 26,250 $0 0 D
Explanation of Responses:
1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.
5. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.69 to $31.61 per share, inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $31.96 per share, inclusive.
8. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
9. Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
/s/ Jonathan Allan, Attorney-in-Fact 12/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider stock transactions were reported for Stoke Therapeutics (STOK)?

The filing shows a company director exercised 26,250 performance stock units into common stock on December 3, 2025, then sold several blocks of common shares on December 4 and 5, 2025 at weighted average prices between $30.23 and $31.96 per share.

How many Stoke Therapeutics (STOK) shares does the director hold after these transactions?

After the reported exercise and sales, the director directly owns 62,554 shares of Stoke Therapeutics common stock.

What is the role of the reporting person at Stoke Therapeutics (STOK)?

The reporting person is identified as a Director of Stoke Therapeutics, Inc., and the Form 4 is filed for one reporting person.

Did the Stoke Therapeutics (STOK) director use a Rule 10b5-1 trading plan?

Yes. Certain transactions on December 5, 2025 were effected under a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

What were the exercise and vesting terms of the Stoke Therapeutics performance stock units?

Each performance stock unit represented a contingent right to receive one share of common stock upon settlement. The reported award vested in two equal parts, with half vesting on December 3, 2024 and the remainder vesting or scheduled to vest on December 3, 2025, subject to continued service.

What exercise price applied to the Stoke Therapeutics performance stock units converted in this filing?

The 26,250 performance stock units reported as exercised on December 3, 2025 converted into common stock at an exercise price of $0 per unit.